Chiome Bioscience Inc. (4583) Press Release
Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30,2026
Earlier from Chiome Bioscience
- Chiome Bioscience: Announcement of target-specific research and option agreement with Heidelberg Pharma
- Chiome Bioscience: Service agreement with option contract with Rohto Pharmaceutical Co., Ltd.
- Chiome Bioscience: First patient in of cancer therapeutic antibody CBA-1535 in a Phase 1 clinical trial
- Chiome Bioscience: Conclusion of contract with additional institutes and first dosing of CBA-1205 in the second part of Phase 1 study